Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

30.17 -1.40 (-4.43%)
Streaming Delayed Price Updated: 2:32 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Which stocks are moving on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
 
Via Benzinga
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
From Neurogene Inc.
Via Business Wire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.